Lifecore Biomedical (NASDAQ:LFCR) Research Coverage Started at Craig Hallum

Craig Hallum started coverage on shares of Lifecore Biomedical (NASDAQ:LFCR) in a research note published on Thursday, Marketbeat Ratings reports. The brokerage issued a buy rating and a $8.00 price objective on the stock.

Separately, Barrington Research downgraded shares of Lifecore Biomedical from an outperform rating to a market perform rating in a report on Wednesday, August 28th.

Lifecore Biomedical Price Performance

NASDAQ LFCR opened at $4.77 on Thursday. The company has a current ratio of 2.08, a quick ratio of 0.99 and a debt-to-equity ratio of 12.90. The company has a fifty day simple moving average of $5.27 and a 200 day simple moving average of $5.92. The company has a market cap of $144.64 million, a P/E ratio of -1.42 and a beta of 0.95. Lifecore Biomedical has a 1 year low of $3.68 and a 1 year high of $8.90.

Lifecore Biomedical (NASDAQ:LFCR) last posted its quarterly earnings data on Friday, August 9th. The company reported ($0.05) earnings per share (EPS) for the quarter. The firm had revenue of $35.70 million for the quarter. Lifecore Biomedical had a negative return on equity of 515.12% and a net margin of 9.37%. On average, sell-side analysts predict that Lifecore Biomedical will post -0.73 EPS for the current year.

Institutional Trading of Lifecore Biomedical

A number of hedge funds have recently bought and sold shares of LFCR. Allegheny Financial Group LTD bought a new stake in Lifecore Biomedical in the 2nd quarter valued at $52,000. Renaissance Technologies LLC bought a new position in shares of Lifecore Biomedical during the 2nd quarter worth about $56,000. SG Americas Securities LLC bought a new position in shares of Lifecore Biomedical during the 1st quarter worth about $57,000. Mirae Asset Global Investments Co. Ltd. bought a new position in shares of Lifecore Biomedical during the 1st quarter worth about $58,000. Finally, Boston Partners bought a new position in shares of Lifecore Biomedical during the 1st quarter worth about $104,000. 83.36% of the stock is owned by institutional investors.

About Lifecore Biomedical

Lifecore Biomedical, Inc, together with its subsidiaries, operates as an integrated contract development and manufacturing organization in the United States and internationally. The company engages in the manufacturing of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a range of medical conditions and procedures.